Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy

QR Code

Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy

Background: There is no published data on the response and survival of Malaysian patients with locally advanced or metastatic adenocarcinoma of the lung with and without epidermal growth factor receptor (EGFR) mutations treated with EGFRtyrosine kinase inhibitors (TKIs) or cytotoxic chemotherapy. O...

Full description

Bibliographic Details
Main Author:	Chai, Chee She
Format:	Thesis
Language:	English
Published:	Universiti of Malaya 2015
Subjects:	R Medicine (General)
Online Access:	http://ir.unimas.my/id/eprint/10817/ http://ir.unimas.my/id/eprint/10817/2/Dr%20Chai%20Chee%20Shee%20ft.pdf

Similar Items

Case Series of Small Cell Lung Cancer Transformation as Resistance Mechanism to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)

Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
by: Chai, C.S., et al.
Published: (2017)

An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)

Epidermal Growth Factor Receptor Mutation in Newly Diagnosed Lung Adenocarcinoma
by: Chee, Shee Chai, et al.
Published: (2017)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)

Epidermal growth factor receptormutations in lung adenocarcinoma in Malaysian patients
by: Liam, Chong Kin, et al.
Published: (2013)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)

Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)

Anaplastic lymphoma kinase (ALK) gene rearrangement in Malaysian patients with lung adenocarcinoma / Noraini Mohamad
by: Noraini, Mohamad
Published: (2017)

Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)

Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy
by: Fareed, Khaleel R., et al.
Published: (2012)

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)

A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)

Epidermal growth factor receptor (EGFR) mutations are the main oncogenic driver mutation in adenocarcinoma in never-smokers - findings from the emlan study
by: Liam, Chong Kin, et al.
Published: (2012)

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

In-vitro cytotoxicity of Trigona itama honey against human lung adenocarcinoma epithelial cell line (A549)
by: Mohd Salim, Siti Norfitrah, et al.
Published: (2019)

Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)

Metastatic adenocarcinoma of the lung mimicking spinal tuberculosis
by: Zakaria@Mohamad, Zamzuri, et al.
Published: (2011)

A prospective study on epidermal growth factor receptor mutations in non-small cell lung cancer in Malaysian patients
by: Liam, C K, et al.
Published: (2012)

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population
by: Liam, Chong-Kin, et al.
Published: (2014)

Targeting the hypoxic expression of epidermal growth factor receptor
by: Alamoudi, Abdulmohsin
Published: (2021)

Ornithine decarboxylase gene expression in human lung adenocarcinoma cell (A549) treated with pomegranate juice
by: Abdul Ghani, Radiah, et al.
Published: (2015)

Identification of anti-proliferative kinase inhibitors as potential therapeutic agents to treat canine osteosarcoma
by: Mauchle, Ulrike, et al.
Published: (2015)

Translational control of epidermal growth factor receptor in neurodegenerative diseases
by: Smalley, Daniel. S.
Published: (2017)

Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)

The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)

A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)

Cytotoxic Activities of Physalis minima L. Chloroform Extract on Human Lung Adenocarcinoma NCI-H23 Cell Lines by Induction of Apoptosis
by: Ooi, Kheng Leong, et al.
Published: (2011)

Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients
by: Ng, Tiffany Shi Yeen, et al.
Published: (2013)

The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)

The cytotoxicity effects of spermidine sulphur analogues Type 1 (SSA-1) and Type 2 (SSA-2) against human lung adenocarcinoma cells (A549), human colorectal adenocarcinoma cells (HCT-8), and human breast adenocarcinoma cells (MCF-7)
by: Jamil, Masnizahani, et al.
Published: (2017)